The research on Ovarian cancer and Endometrial cancer is part of her Cancer project. Elizabeth M. Swisher conducts interdisciplinary study in the fields of Internal medicine and Gastroenterology through her works. She brings together Gastroenterology and Internal medicine to produce work in her papers. Oncology and Gynecology are two areas of study in which Elizabeth M. Swisher engages in interdisciplinary work. Gynecology and Oncology are two areas of study in which she engages in interdisciplinary work. Linguistics and Correlative are frequently intertwined in her study. Her Correlative study frequently draws connections to adjacent fields such as Linguistics. Her study connects Surgery and Ileus. Her Surgery study frequently draws connections between adjacent fields such as Ileus.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer.
Katherine A. Hoadley;Christina Yau;Christina Yau;Toshinori Hinoue;Denise M. Wolf.
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
Robert L Coleman;Amit M Oza;Domenica Lorusso;Carol Aghajanian.
The Lancet (2017)
Secondary mutations as a mechanism of cisplatin resistance in BRCA2 -mutated cancers
Wataru Sakai;Elizabeth M. Swisher;Beth Y. Karlan;Mukesh K. Agarwal.
Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing
Tom Walsh;Silvia Casadei;Ming K. Lee;Christopher C. Pennil.
Proceedings of the National Academy of Sciences of the United States of America (2011)
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial
Elizabeth M Swisher;Kevin K Lin;Amit M Oza;Clare L Scott.
Lancet Oncology (2017)
Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.
Tom Walsh;Silvia Casadei;Kathryn Hale Coats;Elizabeth Swisher.
Germline and Somatic Mutations in Homologous Recombination Genes Predict Platinum Response and Survival in Ovarian, Fallopian Tube, and Peritoneal Carcinomas
Kathryn P. Pennington;Tom Walsh;Maria I. Harrell;Ming K. Lee.
Clinical Cancer Research (2014)
Inherited Mutations in Women With Ovarian Carcinoma
Barbara M. Norquist;Maria I. Harrell;Mark F. Brady;Tom Walsh.
JAMA Oncology (2016)
Genomic and Functional Approaches to Understanding Cancer Aneuploidy
Alison M. Taylor;Alison M. Taylor;Juliann Shih;Gavin Ha;Gavin Ha;Galen F. Gao.
Cancer Cell (2018)
Secondary Somatic Mutations Restoring BRCA1/2 Predict Chemotherapy Resistance in Hereditary Ovarian Carcinomas
Barbara Norquist;Kaitlyn A. Wurz;Christopher C. Pennil;Rochelle Garcia.
Journal of Clinical Oncology (2011)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: